X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs ADCOCK INGRAM (S. Africa) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   ADCOCK INGRAM
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
ADCOCK INGRAM
Jun-14
SUN PHARMA/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs701367-   
Low Rs433265-   
Sales per share (Unadj.) Rs110.4109.1-  
Earnings per share (Unadj.) Rs11.0-27.5-  
Cash flow per share (Unadj.) Rs17.2-22.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.40-  
Book value per share (Unadj.) Rs158.885.7-  
Shares outstanding (eoy) m2,399.26168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.12.9 177.4%   
Avg P/E ratio x51.6-11.5 -449.7%  
P/CF ratio (eoy) x32.9-13.9 -237.5%  
Price / Book Value ratio x3.63.7 96.8%  
Dividend payout %18.20-   
Avg Mkt Cap Rs m1,360,02153,291 2,552.1%   
No. of employees `00017.84.3 414.4%   
Total wages/salary Rs m53,6713,345 1,604.7%   
Avg. sales/employee Rs Th14,890.94,290.3 347.1%   
Avg. wages/employee Rs Th3,017.1779.1 387.3%   
Avg. net profit/employee Rs Th1,480.6-1,081.1 -137.0%   
INCOME DATA
Net Sales Rs m264,89518,418 1,438.2%  
Other income Rs m8,388129 6,503.1%   
Total revenues Rs m273,28218,547 1,473.4%   
Gross profit Rs m56,081-3,192 -1,757.0%  
Depreciation Rs m14,998795 1,886.8%   
Interest Rs m5,176499 1,037.4%   
Profit before tax Rs m44,295-4,357 -1,016.7%   
Minority Interest Rs m0-12 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,5050-   
Tax Rs m8,452272 3,104.7%   
Profit after tax Rs m26,338-4,641 -567.5%  
Gross profit margin %21.2-17.3 -122.2%  
Effective tax rate %19.1-6.2 -305.4%   
Net profit margin %9.9-25.2 -39.5%  
BALANCE SHEET DATA
Current assets Rs m316,35913,490 2,345.1%   
Current liabilities Rs m198,6437,590 2,617.2%   
Net working cap to sales %44.432.0 138.7%  
Current ratio x1.61.8 89.6%  
Inventory Days Days95111 85.5%  
Debtors Days Days108124 86.9%  
Net fixed assets Rs m213,1787,863 2,711.1%   
Share capital Rs m2,39986 2,805.7%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,00614,456 2,635.5%   
Long term debt Rs m17,7215,080 348.8%   
Total assets Rs m643,02827,309 2,354.6%  
Interest coverage x9.6-7.7 -123.6%   
Debt to equity ratio x00.4 13.2%  
Sales to assets ratio x0.40.7 61.1%   
Return on assets %4.9-15.2 -32.3%  
Return on equity %6.9-32.1 -21.5%  
Return on capital %10.0-19.8 -50.6%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,0721,572 2,485.2%  
From Investments Rs m-33,708-483 6,982.9%  
From Financial Activity Rs m-15,3934,611 -333.8%  
Net Cashflow Rs m-7,3595,700 -129.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.06 Rs / ZAR

Compare SUN PHARMA With: MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: J.B.CHEMICALS  ELDER PHARMA  ALEMBIC PHARMA  GLENMARK PHARMA  NOVARTIS  



Today's Market

Sensex Ends 274 Points Lower; IT and Energy Stocks Witness Selling(Closing)

Share markets in India continued to witness selling pressure during closing hours and ended their trading session on a negative note.

Related Views On News

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 19, 2018 | Updated on Sep 19, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 446.1% (Quarterly Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

For the quarter ended June 2018, SUN PHARMA has posted a net profit of Rs 11 bn (up 446.1% YoY). Sales on the other hand came in at Rs 72 bn (up 16.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 21, 2018 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS